Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

T HEMANTH RAO

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1023070745
CMS profile
677428
Location
CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$5.57

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Education $5.57 2

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Retrophin, Inc. $5.57 2

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

T HEMANTH RAO

NPI 1023070745 · CMS profile ID 677428

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1023070745?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
T HEMANTH RAO, NPI 1023070745, CMS profile ID 677428. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1023070745?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). T HEMANTH RAO, NPI 1023070745, CMS profile ID 677428. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1023070745?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
T HEMANTH RAO, NPI 1023070745, CMS profile ID 677428, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1023070745?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $5.57 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Retrophin, Inc. $0.8302/12/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701819007 CMS
Retrophin, Inc. $4.7402/12/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701819009 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $5.57 2
PY2022 $0.83 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022
Generated from
OP_DTL_GNRL_PGYR2022_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $590,566.02 42
PY2024 Principal investigator $757,803.02 58
PY2023 Principal investigator $705,507.39 95
PY2022 Recipient $3,120.00 1
PY2022 Principal investigator $783,014.66 39
PY2021 Principal investigator $424,194.70 79
PY2020 Principal investigator $514,521.07 71
PY2019 Principal investigator $249,052.37 33

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

79 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 UCB SA $576.00 12/20/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 844229819
Principal investigator 1 UCB SA $318.00 12/20/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 844229999
Principal investigator 1 F. Hoffmann-La Roche AG $3,550.00 12/14/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
SECOND PHASE III IN RMS No dispute reported 06/30/2026 836030115
Principal investigator 1 Roche Products Limited $1,850.00 11/29/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD No dispute reported 06/30/2026 836030103
Principal investigator 1 Roche Products Limited $925.00 11/29/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD No dispute reported 06/30/2026 836030109
Principal investigator 1 UCB SA $4,768.00 11/08/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 844231847
Principal investigator 1 UCB SA $3,525.00 11/01/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy CIDP No dispute reported 06/30/2026 844228019
Principal investigator 1 UCB SA $788.00 10/29/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy CIDP No dispute reported 06/30/2026 844227847
Principal investigator 1 UCB SA $1,900.00 10/25/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE P.A.
A MULTICENTER, RANDOMIZED, SUBJECT-BLIND, INVESTIGATOR-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF UCB7665 IN SUBJECTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY No dispute reported 06/30/2026 844227813
Principal investigator 1 Roche Products Limited $700.00 10/21/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD No dispute reported 06/30/2026 836030091
Principal investigator 1 UCB SA $10,078.00 10/21/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 844227501
Principal investigator 1 Roche Products Limited $1,850.00 10/18/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD No dispute reported 06/30/2026 836030097
Principal investigator 1 Roche Products Limited $2,750.00 10/14/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD No dispute reported 06/30/2026 836030085
Principal investigator 1 H. Lundbeck A S $106.25 10/13/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE OF PA
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090271
Principal investigator 1 UCB SA $3,012.00 10/11/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 844227477
Principal investigator 1 UCB SA $658.00 10/11/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 844227481
Principal investigator 1 UCB SA $4,518.00 10/11/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 844227483
Principal investigator 1 UCB SA $574.00 10/11/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 844227485
Principal investigator 1 Novartis Pharmaceuticals Corporation $69,923.36 09/29/2021 Non-covered Recipient Entity
NEUROLOGICAL INSTITUTE
AN OPEN-LABEL MULTICENTER STUDY TO ASSESS RESPONSE TO COVID-19 VACCINE IN PARTICIPANTS WITH MULTIPLE SCLEROSIS TREATED WITH OFATUMUMAB 20 MG SUBCUTANEOUSLY No dispute reported 06/30/2026 800636529
Principal investigator 1 Roche Products Limited $5,500.00 09/28/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
SATRALIZUMAB OPEN LABEL TREATMENT STUDY IN PATIENTS WITH NMOSD No dispute reported 06/30/2026 836030013
Principal investigator 1 Roche Products Limited $2,500.00 09/28/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
SATRALIZUMAB OPEN LABEL TREATMENT STUDY IN PATIENTS WITH NMOSD No dispute reported 06/30/2026 836030019
Principal investigator 1 Roche Products Limited $4,000.00 09/28/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
SATRALIZUMAB OPEN LABEL TREATMENT STUDY IN PATIENTS WITH NMOSD No dispute reported 06/30/2026 836030025
Principal investigator 1 H. Lundbeck A S $1,391.25 09/09/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE OF PA
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090141
Principal investigator 1 F. Hoffmann-La Roche AG $29,349.00 09/07/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, P.A.
SECOND PHASE III IN RMS No dispute reported 06/30/2026 836030133
Principal investigator 1 H. Lundbeck A S $500.00 08/25/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE OF PA
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090101
Principal investigator 1 H. Lundbeck A S $1,876.25 08/19/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE OF PA
A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY No dispute reported 06/30/2026 853090087
Principal investigator 1 Roche Products Limited $1,850.00 08/12/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD No dispute reported 06/30/2026 836030079
Principal investigator 1 UCB SA $5,503.00 08/12/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 844228443
Principal investigator 1 UCB SA $1,275.00 08/12/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 844229563
Principal investigator 1 UCB SA $3,846.00 08/12/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 844229637
Principal investigator 1 F. Hoffmann-La Roche AG $3,610.00 08/10/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, P.A.
SECOND PHASE III IN RMS No dispute reported 06/30/2026 836030127
Principal investigator 1 Roche Products Limited $2,497.51 07/22/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD No dispute reported 06/30/2026 836030071
Principal investigator 1 Roche Products Limited $2,682.00 07/15/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, P.A.
PHASE II STUDY IN RRMS No dispute reported 06/30/2026 836030145
Principal investigator 1 Roche Products Limited $700.00 07/08/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD No dispute reported 06/30/2026 836030067
Principal investigator 1 UCB SA $108.56 06/30/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
AN OPEN-LABEL EXTENSION STUDY TO EVALUATE ROZANOLIXIZUMAB IN STUDY PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS No dispute reported 06/30/2026 844226537
Principal investigator 1 UCB SA $924.00 06/29/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 844224699
Principal investigator 1 UCB SA $4,203.00 06/29/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 844224703
Principal investigator 1 UCB SA $6,564.00 06/24/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 844225413
Principal investigator 1 UCB SA $1,582.00 05/27/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy CIDP No dispute reported 06/30/2026 844226191
Principal investigator 1 F. Hoffmann-La Roche AG $2,958.00 05/25/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, P.A.
SECOND PHASE III IN RMS No dispute reported 06/30/2026 836030121
Principal investigator 1 UCB SA $6,846.00 05/24/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 844226189
Principal investigator 1 UCB SA $2,406.00 05/17/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 844226575
Principal investigator 1 Roche Products Limited $2,682.00 05/11/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, P.A.
PHASE II STUDY IN RRMS No dispute reported 06/30/2026 836030139
Principal investigator 1 UCB SA $9,966.00 04/22/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 844224577
Principal investigator 1 UCB SA $11,031.75 04/22/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy CIDP No dispute reported 06/30/2026 844226825
Principal investigator 1 Roche Products Limited $4,140.00 04/19/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD No dispute reported 06/30/2026 836030061
Principal investigator 1 UCB SA $2,549.00 04/15/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 844224419
Principal investigator 1 UCB SA $2,276.00 04/15/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy CIDP No dispute reported 06/30/2026 844224421
Principal investigator 1 UCB SA $1,346.29 04/14/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
A PHASE 3, RANDOMIZED, DOUBL-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING EFFICACY AND SAFETY OF ROZANOLIXIZUMAB IN ADULT PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS No dispute reported 06/30/2026 844224053
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,247.20 04/07/2021 Non-covered Recipient Entity
NEUROLOGICAL INSTITUTE PA
LONG TERM PROSPECTIVE MULTINATIONAL PARALLEL COHORT STUDY MONITORING SAFETY IN PATIENTS WITH MULTIPLE SCLEROSIS NEWLY STARTED WITH FINGOLIMOD ONCE DAILY OR TREATED WITH ANOTHER APPROVED DISEASE MODIFYING THERAPY No dispute reported 06/30/2026 800636541
Principal investigator 1 UCB SA $2,258.00 03/29/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 844223821
Principal investigator 1 UCB SA $6,904.00 03/29/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 844223953
Principal investigator 1 SK Life Science, Inc. $7,124.60 03/27/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE P.A
1-Q3RAS No dispute reported 06/30/2026 826788411
Principal investigator 1 UCB SA $7,889.75 03/25/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 844223809
Principal investigator 1 SK Life Science, Inc. $500.00 03/23/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE P.A
1-Q3RAS No dispute reported 06/30/2026 826788409
Principal investigator 1 SK Life Science, Inc. $500.00 03/23/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE P.A
1-Q3RAS No dispute reported 06/30/2026 826788423
Principal investigator 1 UCB SA $4,009.00 03/18/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE P.A.
A MULTICENTER, RANDOMIZED, SUBJECT-BLIND, INVESTIGATOR-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF UCB7665 IN SUBJECTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY ( No dispute reported 06/30/2026 844223735
Principal investigator 1 UCB SA $9,547.00 03/01/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 844223645
Principal investigator 1 Roche Products Limited $1,850.00 02/25/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD No dispute reported 06/30/2026 836030049
Principal investigator 1 Roche Products Limited $700.00 02/25/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD No dispute reported 06/30/2026 836030055
Principal investigator 1 UCB SA $3,725.00 02/25/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 844223439
Principal investigator 1 UCB SA $11,958.00 02/25/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 844223441
Principal investigator 1 UCB SA $9,547.00 02/18/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 844223207
Principal investigator 1 UCB SA $3,612.00 02/18/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy CIDP No dispute reported 06/30/2026 844223231
Principal investigator 1 UCB SA $1,700.00 02/11/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE P.A.
A MULTICENTER, RANDOMIZED, SUBJECT-BLIND, INVESTIGATOR-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF UCB7665 IN SUBJECTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY ( No dispute reported 06/30/2026 844223007
Principal investigator 1 Roche Products Limited $1,850.00 02/08/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD No dispute reported 06/30/2026 836030043
Principal investigator 1 UCB SA $810.00 02/08/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE P.A.
A MULTICENTER, RANDOMIZED, SUBJECT-BLIND, INVESTIGATOR-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF UCB7665 IN SUBJECTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY ( No dispute reported 06/30/2026 844223005
Principal investigator 1 UCB SA $5,188.00 02/08/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 844223043
Principal investigator 1 UCB SA $1,702.00 02/08/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 844223143
Principal investigator 1 UCB SA $9,730.30 01/28/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 844222655
Principal investigator 1 Novartis Pharmaceuticals Corporation $76,196.86 01/25/2021 Non-covered Recipient Entity
NEUROLOGICAL INSTITUTE
AN OPEN LABEL SINGLE ARM MULTI CENTER EXTENSION STUDY EVALUATING LONG TERM SAFETY TOLERABILITY AND EFFECTIVENESS OF OFATUMUMAB IN SUBJECTS WITH RELAPSING MULTIPLE SCLEROSIS No dispute reported 06/30/2026 800636535
Principal investigator 1 Roche Products Limited $2,497.51 01/18/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD No dispute reported 06/30/2026 836030037
Principal investigator 1 UCB SA $5,046.00 01/13/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 844222057
Principal investigator 1 Roche Products Limited $981.51 01/07/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE PA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD No dispute reported 06/30/2026 836030031
Principal investigator 1 UCB SA $1,614.00 01/07/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE, PA
An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 844222193
Principal investigator 1 UCB SA $1,218.75 01/07/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE P.A.
A MULTICENTER, RANDOMIZED, SUBJECT-BLIND, INVESTIGATOR-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF UCB7665 IN SUBJECTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY ( No dispute reported 06/30/2026 844222971
Principal investigator 1 UCB SA $1,700.00 01/07/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE P.A.
A MULTICENTER, RANDOMIZED, SUBJECT-BLIND, INVESTIGATOR-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF UCB7665 IN SUBJECTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY No dispute reported 06/30/2026 844222973
Principal investigator 1 UCB SA $220.00 01/07/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE P.A.
A MULTICENTER, RANDOMIZED, SUBJECT-BLIND, INVESTIGATOR-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF UCB7665 IN SUBJECTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY No dispute reported 06/30/2026 844222975
Principal investigator 1 UCB SA $336.00 01/04/2021 Non-covered Recipient Entity
THE NEUROLOGICAL INSTITUTE P.A.
A MULTICENTER, RANDOMIZED, SUBJECT-BLIND, INVESTIGATOR-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF UCB7665 IN SUBJECTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY ( No dispute reported 06/30/2026 844222977